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720a Wednesday, February 29, 2012showed more non-muscle myosin IIb. Mechanical induction was mediated via
focal adhesions; vinculin assembled earlier in ASCs. Inhibiting fibronectin-
integrin binding using alpha 5 or V integrin siRNA blocked mechanosensing
process as ASCs fail to ‘feel’ myogenic 10kPa gel and to show myogenic
mRNA expression. Together these data imply enhanced mechanosensitivity
for ASCs, making them a better therapeutic cell source for fibrotic muscle.
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Changes in Calcium ion balance in muscle fraction has been connected to oc-
currence of spontaneous bioelectrical activities. These changes would result in
an unstable membrane potential and therefore, involuntary action potentials
start to fire on individual single muscle fibers, called fibrillation potentials. Ev-
idence of fibrillation potentials is a hallmark of muscular degenerative diseases,
such as Amyotrophic Lateral Sclerosis (ALS). Detection of fibrillation poten-
tials is typically done by inserting needle electrodes. However, there are
some uncertainties, reported by some studies with regard to origins of detected
fibrillation potentials, suggesting that these oscillatory potentials could be an
artifact of needle insertion and a result of muscle fibers injured by the needle.
In this work, baseline electromyographic (EMG) signals from control subjects
and subjects with ALS are compared. The signals are recorded non-invasively
using high-density surface EMG electrodes. The data are analyzed in frequency
domain, since fibrillation potentials are not detectable on surface EMG in time
domain. Significant differences at some frequency bands are observed, and dif-
ferent underlying reasons are discussed.
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Duchenne muscular dystrophy (DMD) and other dystrophies arising from mu-
tations in the dystrophin/dystroglycan complex produce pathology, at least in
part, due to sarcolemmal membrane fragility, and several other forms of mus-
cular dystrophy have been linked to defective membrane repair. A therapeutic
approach to increase the capacity of muscle cells to reseal their membranes
following mechanical disruption could address both of these mechanisms
and acts as a therapy for improving muscular dystrophy pathology. MG53,
a muscle-specific TRIM-family protein, is an essential component of the acute
membrane repair machinery. In an effort to translate these basic science find-
ings into therapeutic interventions for muscular dystrophy, our studies found
that membrane injury in many cell types leads to exposure of phosphatidylser-
ine (PS) to the extracellular space that can be bound by purified recombinant
human MG53 protein (rhMG53). PS is normally sequestered on the inner leaf-
let of health cells until a disruption in the membrane causes PS to flow onto
the outer leaflet of the membrane. rhMG53 binding increases the capacity of
targeted cells to repair membrane damage when provided in the extracellular
space. This membrane repair action of extracellular rhMG53 could be in-
hibited by competition with additional PS. Intravenuous delivery of
rhMG53 to wild type mice can ameliorate cardiotoxin-induced damage to
skeletal muscle fibers. Subcutaneous injection of rhMG53 allowed for deliv-
ery of rhMG53 to the bloodstream and reduced the severity of pathology in
the mdx rodent model of muscular dystrophy. These findings suggest that re-
combinant MG53 protein can enhance the membrane repair capacity in skel-
etal muscle, and potentially act as a therapeutic agent for the treatment of
muscular dystrophy.
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Prolongation of the Q-T interval, an important electrocardiogram (ECG) pa-
rameter, has been a major cardiac safety concern because it can lead to poten-
tially fatal arrhythmia. The identification of compounds with potential Q-Tprolongation liability is becoming critical in the discovery and selection of can-
didates for drug development. To assess the effects of compounds on the dura-
tion of cardiac action potentials, which are related to the Q-T interval, we have
developed plate-based membrane potential dye and Ca2þ indicator assays us-
ing human induced pluripotent stem (iPS) cell-derived cardiomyocytes. With
the use of sub-second fluorescence resonance energy transfer (FRET) probes,
the change of membrane potential in cardiomyocytes can be monitored. To de-
termine whether these assays are predictive for human cardiotoxicity, we have
examined the pharmacological effects of selected reference drugs known to tar-
get different classes of cardiac ion channels and receptors. We have demon-
strated that these optical assays are highly sensitive to the inhibition of
cardiac ion channels and able to accurately track drug-induced change of action
potential duration in human iPS-derived cardiomycocytes.
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Tissue-specific elasticity arises from developmental changes that occur in the
environment over time, e.g. ~10-fold myocardial stiffening from E3 to E10
in the chick embryo. Recently, we have shown that pre-cardiac mesodermal
cells plated on top of a thiolated hyaluronic acid (HA) matrix engineered to
mimic this time-dependent stiffening improves cardiomyocyte maturation
compared to cells on static compliant matrices. Here we determined cell-
matrix interactions using in vitro encapsulation assays and in vivo injections.
Improved pre-cardiac and embryonic stem cell (ESC) distribution and viability
was observed when cells were encapsulated and bound to immobilized, thio-
lated fibronectin conjugated to the HA matrix. Though not toxic to cells, we
also assessed HA’s local and systemic biocompatibility. Prior to assembly,
HA was injected subcutaneously into Sprague-Dawley (SD) rats and samples
were removed over a post-injection time course and subject to histological, im-
munological, and mechanical analysis. Histological analysis showed minimal
infiltration of host cells and capsule formation around the matrix. Hematolog-
ical analysis showed no significant systemic immune response was elicited in
pre- vs. post-injection animals for all time points. Most importantly, atomic
force microscopy (AFM) analysis showed dynamically increasing hydrogel
stiffness over time similar to that previously found in vitro. HA was also in-
jected into the hearts of healthy SD rats and subject to histological analysis
over a post-injection time course. Though injection volume prevented mechan-
ical measurement in the myocardium, hydrogel porosity increased, which we
previously correlated with increased stiffness over time for subcutaneous injec-
tions. These in vitro data indicate that the combination of cells and develop-
mentally appropriate matrix stiffness may significantly improve cell
differentiation while in vivo data indicate the injectable feasibility of the HA
matrix into the myocardium in future regenerative studies for treating heart fail-
ure post-myocardial infarction.
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Finding a good and long lasting mitigating approach against ionizing radiation
is a continuous challenge. Pyruvate or tocopherol derivatives have been chosen
for their low toxicity to confirm their intrinsic mitigating properties on L929
mouse fibroblasts against radiation damages up to 72 hours after exposures us-
ing colony forming unit assays.
60Hz magnetic fields (EMF) interact with cells through the induced electrical
field Eind at the membrane surface. In our theoretical model, Eind produces
a counter-ion migration from within the Debye layer resulting into a potential
change of the membrane surface capable to activate cell signaling such as
stress responses. EMF mitigation is presently observed but decreases with
time after radiation exposures. To mimic EMF, changing transiently the intra-
cellular redox potential with 100 microM ferricyanide increased strongly cell
survival after lethal radiation. 0.1 to 4 Gauss EMF up to 4 hours with mitigat-
ing chemical agents are shown to promote cell survival, increasing the equiv-
alent dose ratio from 1.25 (no EMF) to around 2 (with EMF) for pyruvate
derivatives.
After UVC or X-rays, cells stop within their cell cycle for repair transiently cu-
mulating in G2/M phase. Cells are subject to two different programmed death
pathways: apoptosis (G2/M phase) and autophagy (G1, S phases). Flow cytom-
etry shows EMF stimulation unlocking the G2/M blockage towards a transient
